Komórki macierzyste łożyska: charakterystyka biologiczna, realia i perspektywy zastosowania klinicznego

*Khrystyna Nasadiuk, Izabela Zdolińska-Malinowska, Dariusz Boruczkowski

Summary
Placenta is one of the main sources of mesenchymal stem/stromal cells, the applicability and effectiveness of which in treating various diseases were proved by experimental and clinical studies. The paper highlights the biological characteristics of placental stem cells, first of all in terms of their differences and superiority from mesenchymal stem/stromal cells isolated from other tissues, and summarizes available data from preclinical research and clinical trials. Placental stem cells were reported to differentiate in vitro into heart progenitor cells, insulin-producing cells, cells of the pancreas, liver, smooth muscles, osteoblasts, and adipocytes. Studies on animal models revealed the effectiveness of placental stem cells in treating myocardial infarction, type 1 diabetes, acute kidney injury, fibrosis of the liver and lungs, ischemic stroke, Alzheimer’s disease, and spinal cord injury. Completed clinical trials confirmed the safety of placental stem cell therapy in diabetes mellitus type 1 and idiopathic lung fibrosis, safety, and efficacy in diabetic foot disease. Thus, banking of placental stem cells may be considered as a reasonable biological insurance allowing to benefit from the best achievements of regenerative medicine and the list of available stem cell therapies is constantly expanding.

To jest tylko fragment artykułu. Aby przeczytać całość, przejdź do Czytelni medycznej.